Albers Jeffrey W.'s Form 4 filing
Spyre Therapeutics, Inc. (SYRE) · filed Aug 10, 2026
- Accession no.
- 0001636282-26-000102
- Filed
- Aug 10, 2026, 9:31 PM ET
- Trade date
- Aug 7, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.40M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Albers Jeffrey W.CIK 0001638474 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | Common Stock | MOption exerciseAcquired | +5,000 | $10.39 | +$51,950 | 5,000 | Direct | |
| Aug 7, 2026 | Common Stock | SSaleDisposed | −5,000 | $104.47 | −$522,350 | 0 | Direct | |
| Aug 7, 2026 | Common Stock | SSaleDisposed | −8,000 | $104.38 | −$835,040 | 19,360 | Indirect | |
| Aug 7, 2026 | Common Stock | SSaleDisposed | −10,000 | $104.68 | −$1,046,800 | 9,360 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | Common Stock | MOption exerciseDisposed | −5,000 | $0.00 | $0 | 45,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.